Search the Newsreel

Why (ATRA) Price Action Is Critical for Tactical Trading

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake

Point72 entities, including Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a 7.6% beneficial stake in Atara Biotherapeutics (ATRA). This stake, totaling 687,718 shares of common stock, is held by Point72 Associates, LLC, an investment fund managed by …

The Technical Signals Behind (CERT) That Institutions Follow

This article from Stock Traders Daily analyzes Certara Inc. (NASDAQ: CERT) using AI models to provide technical signals for institutional trading strategies. It highlights mixed sentiment, suggesting choppy conditions, and outlines position, momentum, and risk hedging strategies with specific entry, target, and stop-loss levels. …

Tarapur Transformers Ltd is Rated Strong Sell

HC Wainwright Issues Negative Forecast for TARA Earnings

Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA)

TARAPUR Share Price Today - Tarapur Transformers Stock Analysis

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

Dimensional Fund Advisors LP significantly increased its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 133.9% in the first quarter, now holding over 531,000 shares valued at $2.77 million. Other institutional investors have also adjusted their holdings, with hedge funds and institutions collectively owning 38.13% …

Tarapur Transformers reports standalone net loss of Rs 0.44 crore in the June 2026 quarter

Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios

Janus Henderson Group Ltd. has disclosed an 8.4% passive ownership stake in Protara Therapeutics, Inc. (TARA) through its asset managers, holding 4,696,709 shares of common stock. These shares are managed on behalf of client accounts, referred to as Managed Portfolios, with Janus Henderson exercising …

Anatara Lifesciences Ltd (ASX:ANR) Share Price Remains Unchanged as Stock Trades at $0.009

Royal Bank of Canada Trims Holdings in Certara, Inc. $CERT

Royal Bank of Canada reduced its stake in Certara, Inc. by 19.5% in the first quarter, selling 245,200 shares and retaining over 1 million shares. This comes as Certara reported disappointing quarterly results, missing EPS and revenue expectations, with a 10.8% year-over-year revenue decline …

Loss-Making Certara, Inc. (NASDAQ:CERT) Expected To Breakeven In The Medium-Term

This article discusses Certara, Inc.'s financial outlook, focusing on analyst expectations for the company to reach breakeven profitability within the next two years. It highlights the average analyst forecast for revenue growth, the substantial cash balance, and the current valuation based on price-to-sales. The …

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics reported its Q2 2026 financial results, highlighting a productive meeting with the FDA for tabelecleucel, which confirmed the opportunity to resubmit its BLA. The company announced significant cost reductions and expects its current cash and investments to fund operations into mid-2027. Net …

Atara Biotherapeutics Q2 Results: Sales beat estimates, EPS in line

Atara Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of $(0.32), which was in line with analyst estimates. While the company's sales of $630,000 beat the consensus estimate by 71.82%, this figure still represented a significant 96.42% year-over-year decline from $17.575 million, and EPS swung from …

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates

Atara Biotherapeutics Inc (ATRA) reported second-quarter earnings per share of $-0.3200, missing analyst estimates by $0.10. The company's revenue for the quarter was $630K, falling short of the consensus estimate of $2.55M. The stock has seen a decline of -3.71% over the last three …

Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings that matched analyst expectations for a loss of $0.32 per share, while revenue of $0.63 million surpassed estimates. Despite ongoing negative profitability metrics, the stock rose 3.2% after the announcement. Institutional investors hold a significant portion of the …

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary

Atara Biotherapeutics reported second-quarter 2026 results with revenue of $0.63 million, a significant drop from the previous year, and a consolidated net loss of $9 million for the six months ending June 30, 2026. The company experienced a sharp decline in commercial revenue due …

Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Expects Cash and Cost Cuts to Fund Operations Into Mid-2027

Atara Biotherapeutics announced its second-quarter 2026 financial results, highlighting productive discussions with the FDA regarding the resubmission of its tabelecleucel BLA. The company reported a net loss of $4.8 million for the quarter but expects its current cash, cash equivalents, and short-term investments, combined …

H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27

H.C. Wainwright has reiterated its Buy rating for Protara Therapeutics (TARA.US), maintaining a target price of $27. This decision reflects the firm's continued positive outlook on the company's prospects.

Laba DFI Retail Nusantara (HERO) Turun 16,6% di Semester I-2026

Certara, Inc. (CERT) Stock Forecasts

The article provides a stock forecast for Certara, Inc. (CERT), a company focused on accelerating medicines using biosimulation software. It highlights an Argus research report from August 5, 2026, which includes a current price of $8.13 and a price target for CERT. The content …

How Investors Are Reacting To Certara (CERT) Expanding Buybacks Amid Wider Losses And Leadership Changes

Certara (CERT) recently reported Q2 2026 results with higher sales but significantly wider net losses. In response, the company expanded its share repurchase authorization to $150 million and announced leadership changes. This has led to questions about Certara's balance between growth investments, leadership focus, …

Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results

Protara Therapeutics (NASDAQ:TARA) announced its quarterly earnings, reporting a loss of $0.36 per share, which missed the consensus estimate by $0.03. Despite the earnings miss and stock performance, analysts maintain a "Moderate Buy" consensus with an average price target of $26.25. Institutional investors like …

Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals

Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary

Protara Therapeutics, Inc. (TARA) reported a wider net loss of $(21.7)M for Q2 2026, with an EPS of $(0.36), compared to the previous year, as the company increased investments in clinical programs and operational expansion. Key business highlights include advancements in the Phase 2 …

Protara Therapeutics: Q2 Earnings Snapshot

Protara Therapeutics, Inc. (TARA) reported a second-quarter loss of $21.7 million, or 36 cents per share, which missed Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of 33 cents per share. This financial update was generated by Automated Insights …

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics (Nasdaq: TARA) announced its second-quarter 2026 financial results and provided a business update, highlighting significant progress across its clinical pipeline. The company expects to complete enrollment for its ADVANCED-2 trial in BCG-Unresponsive NMIBC patients and redesign the ADVANCED-3 trial to expand into …

Atara Biotherapeutics (ATRA) Earnings Date and Reports 2026 $ATRA

Cerrado Gold Announces Release Date for Second Quarter Financial Results and Conference Call / Webcast

TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF] (“Cerrado” or the “Company”) announces that it will file its second quarter 2026 financial results after market Close on August 18, 2026. Financial results will be posted on SEDAR+ (www.sedarplus.com) under Cerrado’s issuer …

Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline?

Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to release a quarterly update today. This update is expected to provide clarity on the company's program focus, funding discipline, the quality of current demand, and its ability to translate operating priorities into sustainable performance. The article emphasizes that …

TARACHAND Standalone June 2026 Net Sales at Rs 67.63 crore, up 10.74% Y-o-Y